1. Home
  2. TBPH vs WYFI Comparison

TBPH vs WYFI Comparison

Compare TBPH & WYFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$18.67

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

WYFI

WhiteFiber Inc. Ordinary Shares

N/A

Current Price

$17.25

Market Cap

806.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TBPH
WYFI
Founded
2013
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
993.7M
806.5M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
TBPH
WYFI
Price
$18.67
$17.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$27.80
$34.38
AVG Volume (30 Days)
528.0K
1.2M
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.58
N/A
Revenue
$80,327,000.00
$70,202,034.00
Revenue This Year
$70.78
$64.54
Revenue Next Year
N/A
$142.04
P/E Ratio
$32.28
N/A
Revenue Growth
27.12
N/A
52 Week Low
$7.90
$13.91
52 Week High
$20.33
$40.75

Technical Indicators

Market Signals
Indicator
TBPH
WYFI
Relative Strength Index (RSI) 57.92 N/A
Support Level $17.25 N/A
Resistance Level $19.13 N/A
Average True Range (ATR) 0.65 0.00
MACD -0.05 0.00
Stochastic Oscillator 78.72 0.00

Price Performance

Historical Comparison
TBPH
WYFI

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About WYFI WhiteFiber Inc. Ordinary Shares

Whitefiber Inc is a provider of artificial intelligence infrastructure solutions. The company owns high-performance computing data centers and provide cloud-based HPC graphics processing units services, which it terms cloud services, for customers such as AI application and machine learning developers. Its Tier-3 data centers provide hosting and colocation services. Its cloud services support generative AI workstreams, especially training and inference. It has two reportable segments: cloud services and colocation services. The cloud services segment generates revenue from providing high performance computing services to support generative AI workstreams. Colocation services generate revenue by providing customers with physical space, power and cooling within the data center facility.

Share on Social Networks: